Nasal Oxygen Articles & Analysis
2 news found
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
Sitting easily in line and without the need to break the circuit7, Aerogen is suitable for multiple areas across the hospital including those providing mechanical ventilation, non-invasive ventilation, high flow nasal cannula oxygen therapy as well as use in spontaneously breathing patients on wards, emergency departments and outpatients2. ...
ByAerogen